abstract |
The present invention relates to compound 7- [4-([1,1′-biphenyl] -3-ylmethyl) -1-piperazinyl] -2 (3H) -benzoxazolone monomethanesulfonate (INNM, bifeprunox mesylate) The present invention relates to a stable polymorphic form of the present invention, a process for the preparation of the polymorphic form and a pharmaceutical product, in particular a pharmaceutical product for the treatment of psychotic disorders and Parkinson's disease. |